Showing results (161-170 of 444) with videos related to
Sort By:
Pageof 45
ERJ Open Research|July 28, 2020
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?Christopher J Brereton, Timothy Wallis, Michelle Casey, et al.Advances in Experimental Medicine and Biology|May 11, 2021
Ventilatory Support in Patients with COVID-19Paolo Maria Leone, Matteo Siciliano, Jacopo Simonetti, et al.Lung|May 17, 2020
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and ManagementFrancesco Varone, Bruno Iovene, Giacomo Sgalla, et al.Journal of Clinical Medicine|May 14, 2025
Small Airways Disease as a Novel Target for Mepolizumab in Asthma-The SASAM Prospective Real-Life StudyMatteo Bonini, Cristina Boccabella, Francesca Cefaloni, et al.Therapeutic Advances in Respiratory Disease|September 30, 2021
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategiesGiorgio Walter Canonica, Pierluigi Paggiaro, Francesco Blasi, et al.Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 21, 2023
Images in Sarcoidosis: new section of our JournalRobert P Baughman, Antonella Caminati, Claudia Ravaglia, et al.American Journal of Respiratory and Critical Care Medicine|July 17, 2012
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trialsRoland M du Bois, Steven D Nathan, Luca Richeldi, et al.Respiratory Research|November 2, 2024
Patient-centered care in pulmonary fibrosis: access, anticipate, and actDelian E Hofman, Tonia Magrì, Catharina C Moor, et al.Advances in Therapy|August 9, 2020
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance DataJoseph A Lasky, Gerard J Criner, Howard M Lazarus, et al.ERJ Open Research|May 3, 2019
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stageChristopher J Ryerson, Martin Kolb, Luca Richeldi, et al.Pageof 45